Rein Therapeutics, Inc. (RNTX): Total Liabilities
$7.24M
As of 2025-12-31
$10.77M
As of 2026-06-30
+28.9%
3-year compound annual growth
+11.6%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $7.24M | -7.2% | 2026-03-26, Balance as of period end |
| 2024-12-31 | $7.80M | +1.1% | 2026-03-26, Balance as of period end |
| 2023-12-31 | $7.71M | +127.9% | 2025-04-07, Balance as of period end |
| 2022-12-31 | $3.38M | -26.1% | 2024-04-15, Balance as of period end |
| 2021-12-31 | $4.58M | +9.5% | 2023-03-20, Balance as of period end |
| 2020-12-31 | $4.18M | -59.9% | 2022-03-28, Balance as of period end |
| 2019-12-31 | $10.43M | -2.7% | 2021-03-24, Balance as of period end |
| 2018-12-31 | $10.71M | +119.0% | 2020-03-30, Balance as of period end |
| 2017-12-31 | $4.89M | +19.8% | 2019-03-29, Balance as of period end |
| 2016-12-31 | $4.08M | n/a | 2018-04-02, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Rein Therapeutics, Inc. (RNTX) | 2025-12-31 | $7.24M | -7.2% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $71.53B | -6.1% |
| TherapeuticsMD, Inc. (TXMD) | 2025-12-31 | $10.78M | -5.9% |
| Pfizer Inc (PFE) | 2025-12-31 | $121.39B | -2.8% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $117.67B | +8.3% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $99.59M | +24.7% |
| Provectus Biopharmaceuticals, Inc. (PVCT) | 2025-12-31 | $7.00M | +0.4% |
| Lisata Therapeutics, Inc. (LSTA) | 2025-12-31 | $3.14M | -44.7% |
| Heron Therapeutics, Inc. (HRTX) | 2025-12-31 | $241.54M | -9.5% |
Compare RNTX, BMY, TXMD, PFE side by side · Screen every company in Pharmaceutical Preparations ↗